NCT06353152View on ClinicalTrials.gov

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 17, 2023

Primary Completion Date

November 16, 2025

Study Completion Date

November 16, 2025

Conditions
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection

single-/multiple-dose infusion

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Gracell Biopharmaceuticals, Inc.

INDUSTRY

lead

Peking University

OTHER